DIO Corporation (KOSDAQ:039840)
 16,800
 +110 (0.66%)
  Oct 31, 2025, 3:30 PM KST
DIO Corporation Revenue
DIO Corporation had revenue of 40.10B KRW in the quarter ending June 30, 2025, with 158.05% growth. This brings the company's revenue in the last twelve months to 145.05B, up 19.62% year-over-year. In the year 2024, DIO Corporation had annual revenue of 119.65B, down -23.21%.
Revenue (ttm) 
 145.05B
Revenue Growth 
 +19.62%
P/S Ratio 
 1.58
Revenue / Employee 
 301.56M
Employees 
 1,749
Market Cap 
229.55B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 119.65B | -36.17B | -23.21% | 
| Dec 31, 2023 | 155.82B | 24.51B | 18.67% | 
| Dec 31, 2022 | 131.31B | -18.73B | -12.48% | 
| Dec 31, 2021 | 150.04B | 29.98B | 24.97% | 
| Dec 31, 2020 | 120.06B | -7.11B | -5.59% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| Samsung Biologics | 5.03T | 
| Celltrion | 3.75T | 
| Yuhan | 2.17T | 
| SK Biopharmaceuticals | 620.28B | 
| PharmaResearch | 449.81B | 
| Sam Chun Dang Pharm. | 215.10B | 
| ALTEOGEN | 158.06B | 
| LigaChem Biosciences | 148.28B |